Nadav Rosenberg
Angel Investor
London, United Kingdom
Nadav Rosenberg is a seed investor in London focused on Software and Biotechnology. Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 6%
Last updated:
For AI agents: llms.txt
Industries Nadav Rosenberg invests in
Stages Nadav Rosenberg invests in
Countries Nadav Rosenberg invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.1M–$3.1M
- Pre-Seed
- $2M–$2M
- Series A
- $18M–$21M
Investment Focus
Industry
- Software 5 (31%)
- Biotechnology 5 (31%)
- Artificial Intelligence 5 (31%)
- Machine Learning 4 (25%)
- Life Science 3 (19%)
Stage
- Seed 10 (63%)
- Pre-Seed 2 (13%)
- Series A 2 (13%)
Country
- United Kingdom 7 (44%)
- France 1 (6%)
- Israel 1 (6%)
- Singapore 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lindus Therapeutics
|
Lindus Health's mission is to accelerate research for the next generation of health companies. | $18M / Series A / Aug 16, 2023 | |
thymia
|
We use video games based on Neuropsychology alongside analyses of video and speech to make mental health assessments smart, starting with depression.Our online platform empowers clinicians so they can assess depression faster, more accurately and objectively. Our multi-modal depression recognition and tracking system allows us to find the righttreatment in weeks instead of years and we make the entire process enjoyable for the patient. | $3.1M / Seed / Jul 27, 2023 | |
Loops
|
Loops is a no-code analytics platform that provides product and data teams with growth opportunities hidden in their data. | $10M / Seed / Nov 15, 2022 | |
Eden Bio
|
Harnessing nature's potential | $1.2M / Seed / Nov 14, 2022 | |
Exogene
|
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M / Pre-Seed / Apr 25, 2022 | |
|
Exogene
|
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M / Pre-Seed / Apr 25, 2022 | |
|
Exogene
|
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M / Seed / Apr 25, 2022 | |
Flexciton
|
Flexciton is an optimisation technology company that has developed a genuinely unique solution to radically improve the efficiency and productivity of fab manufacturing processes using cutting-edge AI technology. Flexciton enables more semiconductor wafers to be produced for the same cost, faster. Since being founded in May 2016, Flexciton hasrapidly expanded to a team of 45, the majority of whom are engineers and researchers with deep tech expertise.Manufacturing is critical to the human race; everything around us is manufactured. Human innovation has been enabled by manufacturing innovation. Manufacturing has stagnated because innovation has reached the limit of what human intelligence alone is capable of. Further innovation demands Artificial Intelligence.The company's vision is to bring Flexciton optimization technology to every factory in the world to enable manufacturing to operate at a level never before possible. | $20.5M / Series A / Jan 01, 2021 | |
Biomage
|
Biomage specializes in single-cell analysis transforming the life sciences. Our goal is to apply innovative computational methods to extract valuable insight from biological data, fueling cutting-edge research across biological disciplines.Our flagship product, the Biomage Single Cell Platform empowers researchers to take ownership of theirsingle cell data analysis, generating deep biological insight in just a few clicks. | $850K / Seed / Dec 08, 2020 | |
Qantev
|
AI claims platform for health & life insurance | $1.7M / Seed / Nov 05, 2020 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nadav Rosenberg invest in?
Nadav Rosenberg invests primarily in Software, Biotechnology and Artificial Intelligence startups, most often at Seed and Pre-Seed stage. Most of the 16 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Nadav Rosenberg's check size?
Nadav Rosenberg typically joins rounds of $1.1M–$3.1M at Seed, $2M–$2M at Pre-Seed and $18M–$21M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Nadav Rosenberg participates in.
How do I contact Nadav Rosenberg?
Public channels for Nadav Rosenberg include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Nadav Rosenberg last invest?
The most recent investment recorded for Nadav Rosenberg closed in Aug 2023. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
